Serving more than 3,000 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber clinical pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible EHR solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.
We employ a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It’s part of our commitment: not only to scientific excellence, but to you.
Our skilled team of field-specific clinical pathologists, consultants and experts work diligently to stay at the forefront of the ever-changing landscape of a pathology laboratory and health IT. As part of this diligence, we work closely with one another to provide the highest quality, academic-based research and information possible.
Overall, emerging data suggest that ERG oncoprotein detection in PCa is highly concordant with ERG gene fusion status an …»
Plexiform xanthomatous tumor (PXT) is a rare dermal/subcutaneous tumor with unknown etiology. In 2002, Michal et al. rep …»
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). Traditionally, CD is thoug …»
Gastric cancer is associated with substantial morbidity and mortality worldwide. It is the second most common cause of c …»
February 21, 2013
The American Society for Gastrointestinal Endoscopy (ASGE) Foundation has received a donation of $100,000 from Miraca Life Sciences to ASGE's IT&T Capital Campaign, a fundraising project to construct a new facility that will provide cutting-edge technology and training capabilities to significantly optimize current educational opportunities. The donation will be made over five years.
Continue reading
January 15, 2013
Irving, Texas, January 15, 2013 – Miraca Life Sciences is excited to announce the initiation of a new testing protocol that will aid in the management of patients with gastroesophageal adenocarcinoma. This protocol is in response to the 2010 "ToGA" (Trastuzumab in Gastric cancer) clinical trial that demonstrated a clear survival benefit for combining …
Continue reading
Medical Director of Laboratories, Phoenix
Director of GI Pathology, Phoenix